Tags

Type your tag names separated by a space and hit enter

Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats.
Br J Cancer. 2010 Dec 07; 103(12):1840-5.BJ

Abstract

BACKGROUND

microsatellite instability (MSI) is commonly screened using a panel of two mononucleotide and three dinucleotide repeats as recommended by a consensus meeting on MSI tumours held at the National Cancer Institute (Bethesda, MD, USA). According to these recommendations, tumours are classified as MSI-H when at least two of the five microsatellite markers show instability, MSI-L when only one marker shows instability and MSS when none of the markers show instability. Almost all MSI-H tumours are characterised by alterations in one of the four major proteins of the mismatch repair (MMR) system (MLH1, MSH2, MSH6 or PMS2) that renders them MMR deficient, whereas MSI-L and MSS tumours are generally MMR proficient. However, tumours from patients with a pathogenic germline mutation in MSH6 can sometimes present an MSI-L phenotype with the NCI panel. The MSH6 protein is not involved in the repair of mismatches of two nucleotides in length and consequently the three dinucleotide repeats of the NCI panel often show stability in MSH6-deficient tumours.

METHODS

a pentaplex panel comprising five mononucleotide repeats has been recommended as an alternative to the NCI panel to determine tumour MSI status. Several studies have confirmed the sensitivity, specificity and ease of use of the pentaplex panel; however, its sensitivity for the detection of MSH6-deficient tumours is so far unknown. Here, we used the pentaplex panel to evaluate MSI status in 29 tumours known to harbour an MSH6 defect.

RESULTS

MSI-H status was confirmed in 15 out of 15 (100%) cases where matching normal DNA was available and in 28 out of 29 (97%) cases where matching DNA was not available or was not analysed.

CONCLUSION

these results show that the pentaplex assay efficiently discriminates the MSI status of tumours with an MSH6 defect.

Authors+Show Affiliations

INSERM, UMRS 938-Centre de Recherche Saint-Antoine, Equipe 'Instabilité des Microsatellites et Cancers', 184 rue du Faubourg Saint-Antoine, Paris F-75012, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21081928

Citation

You, J-F, et al. "Tumours With Loss of MSH6 Expression Are MSI-H when Screened With a Pentaplex of Five Mononucleotide Repeats." British Journal of Cancer, vol. 103, no. 12, 2010, pp. 1840-5.
You JF, Buhard O, Ligtenberg MJ, et al. Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br J Cancer. 2010;103(12):1840-5.
You, J. F., Buhard, O., Ligtenberg, M. J., Kets, C. M., Niessen, R. C., Hofstra, R. M., Wagner, A., Dinjens, W. N., Colas, C., Lascols, O., Collura, A., Flejou, J. F., Duval, A., & Hamelin, R. (2010). Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. British Journal of Cancer, 103(12), 1840-5. https://doi.org/10.1038/sj.bjc.6605988
You JF, et al. Tumours With Loss of MSH6 Expression Are MSI-H when Screened With a Pentaplex of Five Mononucleotide Repeats. Br J Cancer. 2010 Dec 7;103(12):1840-5. PubMed PMID: 21081928.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. AU - You,J-F, AU - Buhard,O, AU - Ligtenberg,M J L, AU - Kets,C M, AU - Niessen,R C, AU - Hofstra,R M W, AU - Wagner,A, AU - Dinjens,W N M, AU - Colas,C, AU - Lascols,O, AU - Collura,A, AU - Flejou,J-F, AU - Duval,A, AU - Hamelin,R, Y1 - 2010/11/16/ PY - 2010/11/18/entrez PY - 2010/11/18/pubmed PY - 2011/1/7/medline SP - 1840 EP - 5 JF - British journal of cancer JO - Br J Cancer VL - 103 IS - 12 N2 - BACKGROUND: microsatellite instability (MSI) is commonly screened using a panel of two mononucleotide and three dinucleotide repeats as recommended by a consensus meeting on MSI tumours held at the National Cancer Institute (Bethesda, MD, USA). According to these recommendations, tumours are classified as MSI-H when at least two of the five microsatellite markers show instability, MSI-L when only one marker shows instability and MSS when none of the markers show instability. Almost all MSI-H tumours are characterised by alterations in one of the four major proteins of the mismatch repair (MMR) system (MLH1, MSH2, MSH6 or PMS2) that renders them MMR deficient, whereas MSI-L and MSS tumours are generally MMR proficient. However, tumours from patients with a pathogenic germline mutation in MSH6 can sometimes present an MSI-L phenotype with the NCI panel. The MSH6 protein is not involved in the repair of mismatches of two nucleotides in length and consequently the three dinucleotide repeats of the NCI panel often show stability in MSH6-deficient tumours. METHODS: a pentaplex panel comprising five mononucleotide repeats has been recommended as an alternative to the NCI panel to determine tumour MSI status. Several studies have confirmed the sensitivity, specificity and ease of use of the pentaplex panel; however, its sensitivity for the detection of MSH6-deficient tumours is so far unknown. Here, we used the pentaplex panel to evaluate MSI status in 29 tumours known to harbour an MSH6 defect. RESULTS: MSI-H status was confirmed in 15 out of 15 (100%) cases where matching normal DNA was available and in 28 out of 29 (97%) cases where matching DNA was not available or was not analysed. CONCLUSION: these results show that the pentaplex assay efficiently discriminates the MSI status of tumours with an MSH6 defect. SN - 1532-1827 UR - https://www.unboundmedicine.com/medline/citation/21081928/Tumours_with_loss_of_MSH6_expression_are_MSI_H_when_screened_with_a_pentaplex_of_five_mononucleotide_repeats_ L2 - https://doi.org/10.1038/sj.bjc.6605988 DB - PRIME DP - Unbound Medicine ER -